With college back in session, the NJ AIDS/HIV/STD Hotline is reminding students they can be independent and enjoy all the social activities without suffering any of the unintentional mistakes such as drug overdose, drug misuse, unplanned pregnancies, sexual assaults and STDs.
to the Hotline, students will experiment with both drugs and alcohol,
along with their sexuality. However, all this experimentation can be
costly and affect their health for all time.
just the U.S., there are about 20 million new STI cases each year;
over half of them being in people between 15 and 24 years of age.
While condoms help to alleviate the chances of an STI, it doesn’t
protect against them completely.
agency said for people to get the most protection, they need to use
condoms effectively and for every sexual act from oral, anal and
vaginal. They also stressed that Ella and Plan B methods were only
good for pregnancies, not STIs or HIV.
warning about drugs and alcohol influence was also given, as they
could lower one’s ability to make sound judgments and increase
their chances of engaging in high-risk behaviors. Such actions
include having unprotected sex, having sex with more than one
partner, having sex with an infected partner, using sex for money or
drugs or sharing needles.
one of these behaviors can lead to STIs and HIV.
sexually-active person is at risk for catching an STI, even if it’s
just one time. Most are spread via bodily fluids but also genital
touching and drug use injections. The Hotline advised students to get
tested even if they show no symptoms of having an STI.
Here’s what we've been up to recently.
The human papilloma virus (HPV) can cause cervical cancers and other cancers as well as sexually transmitted diseases. There are several types of HPV, including the type 16 is the strain that causes almost 50% of cervical cancer and four other strains can also cause cancer. Cervical cancer may occur after cells in the cervix undergo changes due to persistent HPV infection by a single strain of the virus.
The World Health Organization (WHO) is using new evidence about the HIV drug dolutegravir (DTG) to suggest it be the first and second line of treatment for populations such as pregnant women and women of childbearing ages.